



For Immediate Release

Cushman & Wakefield brokered final two LINX leases on behalf of Boylston Properties

Boston (March 29, 2018): [Aileron Therapeutics](#), a clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, will relocate from Cambridge to 18,609 square feet of space, while [Kala Pharmaceuticals, Inc.](#) (NASDAQ: KALA), a biopharmaceutical company focused on the development and commercialization of innovative treatments for ocular diseases will relocate to 66,053 square feet of space within the [LINX](#) building at 490 Arsenal Way in Watertown, announced brokers [Cushman & Wakefield](#) and the building owner, [Boylston Properties](#).

“With the addition of Aileron Therapeutics, LINX is officially at 100% capacity and shows the appeal of the East End of Watertown is alive and well,” said Bill McQuillan, president of Boylston Properties.

“Aileron Therapeutics’ relocation from Cambridge further highlights how desirable the East End of Watertown has become to life sciences companies,” said Duncan Gratton, executive director at Cushman & Wakefield. “Watertown continues to be an attractive location for companies seeking a more affordable alternative to Kendall Square that’s still in close proximity to Cambridge and Boston.”

Gratton and Kate Lien, senior director at Cushman & Wakefield, represented Boylston Properties in the transaction.

Aileron Therapeutics was represented by Dave Townsend, executive managing director at Newmark Knight Frank, in its 18,609-square-foot lease.

Kala Pharmaceuticals was represented by Sam Crossan, Vice President and Rob Walles, Senior Vice President/Partner of CBRE in its 66,052 square foot lease.

Located at 490 Arsenal Way, [LINX](#) is a 185,000-square-foot creative office and lab building in the East End of Watertown, a neighborhood undergoing a tremendous renaissance. The two-story building opened in the summer of 2017 and includes numerous amenities highlighted by an acre of outdoor green and recreation space, a 33-foot high lobby area with a café, bike storage for 78 bicycles and a high-end shower and locker

For Further Information Contact:

Linda McDonough
Marketing Director
+1 617 279 4571
linda.mcdonough@cushwake.com

Media Contact:

Aaron Gouveia
Director
+1 617 646 3309
agouveia@schneiderpr.com



facility. LINX also offers abundant free parking and a private shuttle bus to Harvard Square and the MBTA Red Line.

Cushman & Wakefield's Boston office provides a complete suite of commercial real estate services for the entire lifecycle of properties and portfolios.

About Aileron Therapeutics

Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and other diseases. Stapled peptides are chemically stabilized alpha-helical peptides that are modified to improve their stability and cell penetrability while maintaining high affinity for large protein surfaces. Our goal is to use our proprietary stapled peptide drug platform to create first-in-class therapeutics, like ALRN-6924, that may be able to address historically undruggable targets and complex mechanisms that underlie many diseases with high unmet medical need. Our platform enables us to chemically stabilize and improve the performance and activity of a broad range of alpha-helical peptides that we believe can potentially activate and inhibit key cellular functions that are otherwise difficult to target with existing drug technologies, including small molecules and monoclonal antibodies. For more information, visit www.aileronrx.com.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

About Boylston Properties

Boylston Properties is a 34-year old Boston-based developer of urban mixed-use projects including retail, residential, hotel, office, and research buildings. The company draws upon urban and suburban development experience on its own or with partners in the Northeast U.S. markets, many in the Greater Boston area. Boylston Properties has recently opened the 150 room Marriott Residence Inn Boston/Watertown and is redeveloping Arsenal Yards into an exciting mixed-use neighborhood in Watertown's East End. For more information, please go to www.boylstonproperties.com or <http://www.linxwatertown.com/>.

About Cushman & Wakefield

Cushman & Wakefield is a leading global real estate services firm with 45,000 employees in more than 70 countries helping occupiers and investors optimize the value of their real estate. Cushman & Wakefield is among the largest commercial real estate services firms with revenue of \$6 billion across core services of agency leasing, asset services, capital markets, facility services (C&W Services), global occupier services, investment & asset management (DTZ Investors), project & development services, tenant representation, and valuation & advisory. To learn more, visit www.cushmanwakefield.com or follow [@CushWake](https://twitter.com/CushWake) on Twitter.